Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. · 2021
Read Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. by Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8522627.txt.
Introduction
Packer and co-authors analyze how empagliflozin affects worsening heart failure in patients with preserved ejection fraction. The EMPEROR-Preserved trial had shown the drug cut the combined risk of heart death or hospital stay. That gain came mostly from fewer heart failure admissions.
This analysis digs into the severity of those events. The drug cut the worst admissions, ones needing intensive care or strong support drugs. It also cut outpatient flare-ups, such as urgent visits and stepped-up diuretic use. Declines in daily function class grew less common too. Options for this patient group are few. The authors see broad gains across care settings.
Catalog record
| CREATOR | Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Schnaidt S, Zeller C, Schnee JM, Anker SD. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction By Milton Packer, Javed Butler, Faiez Zannad, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J. Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan Miller Published in: Circulation DOI: 10.1161/CIRCULATIONAHA.121.056824 ABSTRACT Supplemental Digital Content is available in the text. Clinical PerspectiveWhat Is New?EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) showed that, in patients with heart failure and preserved ejection fraction, empagliflozin reduced the primary end point of cardiovascular death or hospitalization for heart failure, primarily related to a 29% lower risk of hospitalizations for heart failure.In the current analysis, we show that empagliflozin reduced the risk of severe hospitalizations, as reflected by admissions requiring the use of positive inotropic and vasopressor drugs and the need for intensive care.Empagliflozin also reduced the risk of outpatient worsening heart failure events, including need for urgent care visits, diuretic intensification, and unfavorable changes in functional class.What Are the Clinical Implications?Therapeutic options for patients with heart failure and preserved ejection fraction are limited; previous trials with various interventions have shown little or modest effects.The favorable effects of empagliflozin on inpatient and outpatient worsening heart failure events in patients with heart failure and preserved ejection fraction in EMPEROR-Preserved are similar to those reported with empagliflozin in patients with heart failure and reduced ejection fraction in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction). Heart failure is a progressive disorder marked by ongoing or episodic worsening of symptoms, leading to a deterioration of functional capacity and requiring intensification of treatment. Often, these episodes of clinical worsening can be managed in an outpatient setting, which can involve an office, clinic, emergency department, or urgent care setting. When severe or of rapid onset, worsening symptoms may require hospitalization, and if the patient becomes clinically unstable, admission to intensive care. Therefore, the clinical progression of heart failure can manifest itself in a broad range of clinical settings. Although the primary end point of clinical trials typically focuses only on hospitalizations,1,2 these represent only a small proportion of a patient’s journey,3,4 and outpatient and inpatient worsening heart failure events can have similar adverse prognostic implications.5–7 In clinical trials in type 2 diabetes or chronic kidney disease, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalizations for heart failure.8–14 However, these trials did not evaluate the effect of these drugs on the broad spectrum of both inpatient and outpatient heart failure events. We and others have reported that in patients with heart failure with reduced ejection fraction, empagliflozin, dapagliflozin, and sotagliflozin not only lowered the risk of hospitalization for heart failure, but also diminished the risk of outpatient events, including emergency or urgent care visits and outpatient intensification of diuretics for worsening heart failure.15–18 In this article, we report on the effect of empagliflozin on inpatient and outpatient worsening heart failure events in patients with heart failure and an ejection fraction >40%. Furthermore, because patients with heart failure with preserved ejection fraction (HFpEF) have comorbidities that can cause serious disability for reasons other than heart failure, we report on the effect of empagliflozin using more comprehensive definitions of death and hospitalization.19–23 METHODS EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction; URL: https://www.clinicaltrials.gov; Unique identifier: NCT0305791) was a randomized, double-blind, parallel-group, placebo-controlled, event-driven study, whose design has been described previously.24,25 Ethics approval was obtained at each study site and informed consent was obtained from all study participants. Data will be made available on request in adherence with transparency conventions in medical research and through requests to the corresponding author. The Executive Committee of the EMPEROR trials (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure) has developed a comprehensive analysis plan and numerous prespecified analyses, which will be presented in future scientific meetings and publications. At a later time point, the full database will be made available in adherence with the transparency policy of the sponsor (available at https://trials.boehringer-ingelheim.com/transparency_policy.html). Study Patients and Assessments We enrolled men or women with chronic heart failure (New York Heart Association [NYHA] functional class II, III, or IV) with a left ventricular ejection fraction >40% who had elevated levels of NT-proBNP (N-terminal prohormone B-type natriuretic peptide) >300 pg/mL; this threshold was tripled in patients with atrial fibrillation at baseline. Patients who fulfilled prespecified inclusion and exclusion criteria were randomized double-blind (in a 1:1 ratio) to receive placebo or empagliflozin 10 mg daily in addition to their usual therapy. After randomization, all appropriate treatments for heart failure or other medical conditions could be initiated or altered at the discretion of the physician of each patient. Patients were assessed at study visits for major outcomes, functional capacity related to heart failure, changes in the use of diuretics, vital signs, and biomarkers reflecting changes in the course of heart failure or the action of SGLT2 inhibitors; these assessments took place every 2 to 6 months, depending on the metric and the duration of follow-up. All randomized patients were to be followed for prespecified outcomes for the entire duration of the trial. Trial End Points In a manner similar to that followed for EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction),15 we prospectively collected information on deaths, hospitalizations for any reason, and emergency, urgent, and outpatient events that reflect worsening heart failure. Hospitalizations were classified as cardiovascular or noncardiovascular on the basis of the judgment of the investigator, but hospitalizations for heart failure were prospectively adjudicated by a clinical event committee in a blinded manner using prespecified criteria. To qualify as an adjudicated heart failure hospitalization, patients were required to have meaningful worsening of their clinical status and intensification of treatment for heart failure. The duration of the in-hospital stay was at least 12 hours; if the patient had not received intravenous medications for heart failure, the minimum stay of an adjudicated heart failure hospitalization was 24 hours. Investigators documented the clinical course of each hospital admission on a dedicated form, including the prescribing of medications used to treat episodes of clinical decompensation and the use of intensive care. In addition to the adjudication and characterization of hospitalizations for heart failure, at each scheduled study visit, patients were prospectively asked about interval events and about changes in the use of diuretics that were prescribed in response to worsening heart failure since the most recent visit. Events that were prospectively considered to reflect meaningful changes in clinical status included (1) worsening heart failure that required the use of an intravenous drug for heart failure in an emergency department or urgent care setting; (2) intensification of daily doses of diuretics for worsening symptoms; and (3) changes in NYHA functional class. Events treated in an emergency department, urgent care setting, or during a hospital stay shorter than that required for an adjudicated event were grouped together. Physicians were not provided any specific guidance as to the degree or duration of diuretic intensification that would qualify as representing a clinically meaningful change. Ascertainment of these events and measures were prospectively collected in the case report form and their inclusion in analyses